{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T21:11:50Z","timestamp":1776114710270,"version":"3.50.1"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"AbbVie Pharmaceuticals"},{"name":"Intercept Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.cld.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T08:03:44Z","timestamp":1583136224000},"page":"303-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel Therapies in Hepatic Encephalopathy"],"prefix":"10.1016","volume":"24","author":[{"given":"Maryam","family":"Alimirah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Sadiq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ajg.2011.314","article-title":"Hospital readmissions among patients with decompensated cirrhosis","volume":"107","author":"Volk","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2020.01.009_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1472-6963-11-149","article-title":"Unplanned readmission rates, length of hospital stay, mortality, and medical costs of ten common medical conditions: a retrospective analysis of Hong Kong hospital data","volume":"11","author":"Wong","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.cld.2020.01.009_bib4","series-title":"Hepatic encephalopathy: management with lactulose and related carbohydrates","author":"Conn","year":"1989"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/17425255.2017.1262843","article-title":"An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease","volume":"13","author":"De Las Heras","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/hep.22917","article-title":"l-Ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure","volume":"50","author":"Ytrebo","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2020.01.009_bib7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep.26611","article-title":"Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy","volume":"59","author":"Rockey","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib8","first-page":"219","article-title":"Sodium benzoate for treatment of hepatic encephalopathy","volume":"9","author":"Misel","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2020.01.009_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-018-1024-1","article-title":"l-Ornithine l-aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses","volume":"79","author":"Butterworth","year":"2019","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/hep.29410","article-title":"l-Ornithine l-aspartate in bouts of overt hepatic encephalopathy","volume":"67","author":"Sidhu","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ymgme.2011.04.013","article-title":"Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate","volume":"103","author":"Lichter-Konecki","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.cld.2020.01.009_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/cpdd.18","article-title":"Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: a pilot study of safety and effect on venous ammonia concentration","volume":"2","author":"Ghabril","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJM195801092580201","article-title":"Management of hepatocerebral intoxication","volume":"258","author":"Manning","year":"1958","journal-title":"N\u00a0Engl J Med"},{"issue":"6945","key":"10.1016\/j.cld.2020.01.009_bib14","first-page":"689","article-title":"The treatment and prognosis of hepatic coma","volume":"271","author":"Dawson","year":"1956","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.15171\/mejdd.2016.46","article-title":"Polyethylene glycol and lactulose versus lactulose alone in the treatment of hepatic encephalopathy in patients with cirrhosis: a non-inferiority randomized controlled trial","volume":"9","author":"Naderian","year":"2017","journal-title":"Middle East J Dig Dis"},{"issue":"3","key":"10.1016\/j.cld.2020.01.009_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cld.2015.04.008","article-title":"Novel ammonia-lowering agents for hepatic encephalopathy","volume":"19","author":"Rahimi","year":"2015","journal-title":"Clin Liver Dis"},{"issue":"11","key":"10.1016\/j.cld.2020.01.009_bib17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/jamainternmed.2014.4746","article-title":"Lactulose vs polyethylene glycol 3350\u2013\u2013electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial","volume":"174","author":"Rahimi","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"12","key":"10.1016\/j.cld.2020.01.009_bib18","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1097\/MEG.0000000000001267","article-title":"Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy","volume":"30","author":"Shehata","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib19","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/hep.24273","article-title":"AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct\u2013ligated rats","volume":"53","author":"Bosoi","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2020.01.009_bib20","doi-asserted-by":"crossref","first-page":"S-997","DOI":"10.1016\/S0016-5085(13)63702-6","article-title":"Su1685 AST-120 (Spherical Carbon Adsorbent) in covert hepatic encephalopathy: results of the astute trial","volume":"144","author":"Bajaj","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2020.01.009_bib21","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/S0168-8278(09)60107-0","article-title":"105 phase 2, multicenter, randomized study of ast-120 (spherical carbon adsorbent) vs. lactulose in the treatment of low-grade hepatic encephalopathy (HE)","volume":"50","author":"Pockros","year":"2009","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib22","article-title":"Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis","author":"Zacharias","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.cld.2020.01.009_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/gut.2007.122176","article-title":"Pathogenetic mechanisms of hepatic encephalopathy","volume":"57","author":"Haussinger","year":"2008","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib24","doi-asserted-by":"crossref","first-page":"G168","DOI":"10.1152\/ajpgi.00190.2011","article-title":"Linkage of gut microbiome with cognition in hepatic encephalopathy","volume":"302","author":"Bajaj","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11011-006-9042-1","article-title":"Role of ammonia and inflammation in minimal hepatic encephalopathy","volume":"22","author":"Shawcross","year":"2007","journal-title":"Metab Brain Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2020.01.009_bib26","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jceh.2014.12.003","article-title":"Gut microbiota: its role in hepatic encephalopathy","volume":"5","author":"Rai","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2020.01.009_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jceh.2012.08.004","article-title":"Gut microbiota, inflammation and hepatic encephalopathy: a puzzle with a solution in sight","volume":"2","author":"Dhiman","year":"2012","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2020.01.009_bib28","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated with cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4161\/gmic.2.2.15416","article-title":"Diversity of the autochthonous colonic microbiota","volume":"2","author":"Nava","year":"2011","journal-title":"Gut Microbes"},{"issue":"9","key":"10.1016\/j.cld.2020.01.009_bib30","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1128\/AEM.67.9.4111-4118.2001","article-title":"Ruminococcin A, a new lantibiotic produced by a Ruminococcus gnavus strain isolated from human feces","volume":"67","author":"Dabard","year":"2001","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.gastro.2015.05.008","article-title":"Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook","volume":"149","author":"Kelly","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hep.28121","article-title":"Fecal microbiota transplantation in the management of hepatic encephalopathy","volume":"63","author":"Kao","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib33","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1053\/j.gastro.2019.01.033","article-title":"Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis","volume":"156","author":"Bajaj","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2020.01.009_bib35","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2020.01.009_bib36","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/liv.12288","article-title":"Probiotics in cirrhosis: do we expect too much?","volume":"33","author":"Soriano","year":"2013","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.cld.2020.01.009_bib37","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/apt.12695","article-title":"Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis","volume":"39","author":"Bajaj","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00063030-200721010-00007","article-title":"Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases","volume":"21","author":"Chapman","year":"2007","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.cld.2020.01.009_bib39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/liv.12566","article-title":"VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis","volume":"35","author":"Sanchez","year":"2015","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.cld.2020.01.009_bib40","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/hep4.1325","article-title":"Effect of a multistrain probiotic on cognitive function and risk of falls in patients with cirrhosis: a randomized trial","volume":"3","author":"Roman","year":"2019","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib41","article-title":"Probiotics for people with hepatic encephalopathy","author":"Dalal","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13073-016-0300-5","article-title":"Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials","volume":"8","author":"Kristensen","year":"2016","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12866-017-1090-7","article-title":"Administration of two probiotic strains during early childhood does not affect the endogenous gut microbiota composition despite probiotic proliferation","volume":"17","author":"Laursen","year":"2017","journal-title":"BMC Microbiol"},{"issue":"30","key":"10.1016\/j.cld.2020.01.009_bib44","doi-asserted-by":"crossref","first-page":"10821","DOI":"10.1523\/JNEUROSCI.0575-15.2015","article-title":"Probiotics improve inflammation-associated sickness behavior by altering communication between the peripheral immune system and the brain","volume":"35","author":"D'Mello","year":"2015","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.cld.2020.01.009_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12937-015-0084-2","article-title":"Detection of antibiotic resistance in probiotics of dietary supplements","volume":"14","author":"Wong","year":"2015","journal-title":"Nutr J"},{"key":"10.1016\/j.cld.2020.01.009_bib46","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fmicb.2017.00908","article-title":"Assessing the risk of probiotic dietary supplements in the context of antibiotic resistance","volume":"8","author":"Zheng","year":"2017","journal-title":"Front Microbiol"},{"issue":"8","key":"10.1016\/j.cld.2020.01.009_bib47","article-title":"Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy","author":"Goh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1021949616422","article-title":"Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy","volume":"17","author":"Jones","year":"2002","journal-title":"Metab Brain Dis"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12974-016-0549-z","article-title":"Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia","volume":"13","author":"Hernandez-Rabaza","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib50","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/hep.510280212","article-title":"Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study","volume":"28","author":"Barbaro","year":"1998","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11011-005-7906-4","article-title":"Limited capacity for ammonia removal by brain in chronic liver failure: potential role of nitric oxide","volume":"20","author":"Rose","year":"2005","journal-title":"Metab Brain Dis"},{"issue":"2\u20133","key":"10.1016\/j.cld.2020.01.009_bib52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0197-0186(02)00033-5","article-title":"Glutamine synthetase in brain: effect of ammonia","volume":"41","author":"Suarez","year":"2002","journal-title":"Neurochem Int"},{"issue":"4 Suppl 1","key":"10.1016\/j.cld.2020.01.009_bib53","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1002\/lt.500060505","article-title":"Brain edema and portal-systemic encephalopathy","volume":"6","author":"Blei","year":"2000","journal-title":"Liver Transpl"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib54","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10545-012-9546-2","article-title":"Ammonia toxicity to the brain","volume":"36","author":"Braissant","year":"2013","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.cld.2020.01.009_bib55","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/hep.510250310","article-title":"Protective effect of l-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat","volume":"25","author":"Therrien","year":"1997","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0006-8993(91)90814-C","article-title":"Suppression of neurotoxicity of ammonia by l-carnitine","volume":"567","author":"Matsuoka","year":"1991","journal-title":"Brain Res"},{"issue":"45","key":"10.1016\/j.cld.2020.01.009_bib57","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.3748\/wjg.v11.i45.7197","article-title":"Effects of l-carnitine in patients with hepatic encephalopathy","volume":"11","author":"Malaguarnera","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib58","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.neuroscience.2009.11.021","article-title":"The neuropathy-protective agent acetyl-l-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain","volume":"165","author":"Di Cesare Mannelli","year":"2010","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1023\/B:JOBB.0000041766.71376.81","article-title":"Protection against ischemic brain injury by inhibition of mitochondrial oxidative stress","volume":"36","author":"Fiskum","year":"2004","journal-title":"J\u00a0Bioenerg Biomembr"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12779\/dnd.2018.17.1.1","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled clinical trial for efficacy of acetyl-l-carnitine in patients with dementia associated with cerebrovascular disease","volume":"17","author":"Yang","year":"2018","journal-title":"Dement Neurocogn Disord"},{"issue":"11","key":"10.1016\/j.cld.2020.01.009_bib61","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1007\/s10620-008-0238-6","article-title":"Acetyl-l-carnitine treatment in minimal hepatic encephalopathy","volume":"53","author":"Malaguarnera","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib62","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3109\/00365521.2011.565067","article-title":"Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy","volume":"46","author":"Malaguarnera","year":"2011","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib63","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3945\/ajcn.110.007393","article-title":"Oral acetyl-l-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study","volume":"93","author":"Malaguarnera","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib64","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11011-011-9260-z","article-title":"Acetyl-l-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial","volume":"26","author":"Malaguarnera","year":"2011","journal-title":"Metab Brain Dis"},{"issue":"1","key":"10.1016\/j.cld.2020.01.009_bib65","article-title":"Acetyl-l-carnitine for patients with hepatic encephalopathy","author":"Marti-Carvajal","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.cld.2020.01.009_bib66","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S1665-2681(19)31323-7","article-title":"Oral acetyl-l-carnitine treatment in hepatic encephalopathy: view of evidence-based medicine","volume":"12","author":"Jiang","year":"2013","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib67","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jceh.2014.08.007","article-title":"Role of human albumin in the management of complications of liver cirrhosis","volume":"4","author":"Bernardi","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2020.01.009_bib68","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.21843","article-title":"Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: Pandora's box?","volume":"46","author":"Wright","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2020.01.009_bib69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1042\/CS20030357","article-title":"Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid","volume":"106","author":"Jalan","year":"2004","journal-title":"Clin Sci (Lond)"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib70","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jhep.2013.07.020","article-title":"Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study","volume":"59","author":"Simon-Talero","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib71","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/jgh.13666","article-title":"Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy","volume":"32","author":"Sharma","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib72","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s11011-015-9713-x","article-title":"No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt","volume":"31","author":"Riggio","year":"2016","journal-title":"Metab Brain Dis"},{"issue":"12","key":"10.1016\/j.cld.2020.01.009_bib73","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1002\/jcp.26881","article-title":"The metabolic and molecular mechanisms of hyperammonaemia -and hyperethanolaemia-induced protein catabolism in skeletal muscle cells","volume":"233","author":"Crossland","year":"2018","journal-title":"J\u00a0Cell Physiol"},{"issue":"45","key":"10.1016\/j.cld.2020.01.009_bib74","doi-asserted-by":"crossref","first-page":"18162","DOI":"10.1073\/pnas.1317049110","article-title":"Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism","volume":"110","author":"Qiu","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"8","key":"10.1016\/j.cld.2020.01.009_bib75","doi-asserted-by":"crossref","first-page":"E983","DOI":"10.1152\/ajpendo.00183.2012","article-title":"Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis","volume":"303","author":"Qiu","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13539-012-0069-3","article-title":"Consilience in sarcopenia of cirrhosis","volume":"3","author":"Dasarathy","year":"2012","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"issue":"9","key":"10.1016\/j.cld.2020.01.009_bib77","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/j.1478-3231.2007.01562.x","article-title":"Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis","volume":"27","author":"Kalaitzakis","year":"2007","journal-title":"Liver Int"},{"issue":"21","key":"10.1016\/j.cld.2020.01.009_bib78","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.3748\/wjg.14.3438","article-title":"Hepatic encephalopathy in patients with liver cirrhosis: is there a role of malnutrition?","volume":"14","author":"Kalaitzakis","year":"2008","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2020.01.009_bib79","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.29107","article-title":"Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis","volume":"65","author":"Kumar","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2020.01.009_bib80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fphar.2019.00132","article-title":"Bicuculline reduces neuroinflammation in hippocampus and improves spatial learning and anxiety in hyperammonemic rats. Role of glutamate receptors","volume":"10","author":"Malaguarnera","year":"2019","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.cld.2020.01.009_bib81","doi-asserted-by":"crossref","first-page":"G400","DOI":"10.1152\/ajpgi.00073.2015","article-title":"GR3027 antagonizes GABAA receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy","volume":"309","author":"Johansson","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cld.2020.01.009_bib82","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12974-015-0420-7","article-title":"Sildenafil reduces neuroinflammation and restores spatial learning in rats with hepatic encephalopathy: underlying mechanisms","volume":"12","author":"Hernandez-Rabaza","year":"2015","journal-title":"J\u00a0Neuroinflammation"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib83","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1053\/j.gastro.2008.12.057","article-title":"Hyperammonemia increases GABAergic tone in the cerebellum but decreases it in the rat cortex","volume":"136","author":"Cauli","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2020.01.009_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12974-016-0505-y","article-title":"Hyperammonemia induces glial activation, neuroinflammation and alters neurotransmitter receptors in hippocampus, impairing spatial learning: reversal by sulforaphane","volume":"13","author":"Hernandez-Rabaza","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"4","key":"10.1016\/j.cld.2020.01.009_bib85","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4196\/kjpp.2019.23.4.263","article-title":"Hepatoprotective effect of sodium hydrosulfide on hepatic encephalopathy in rats","volume":"23","author":"Kwon","year":"2019","journal-title":"Korean J Physiol Pharmacol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612030009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612030009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:56:35Z","timestamp":1761069395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932612030009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S108932612030009X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2020.01.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapies in Hepatic Encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}